English
往期目录
新闻公告
More
化学进展 2011, Vol. 23 Issue (4): 772-780 前一篇   后一篇

• 综述与评论 •

钆类造影剂用于肿瘤靶向性成像

沈爱军, 董海青, 温惠云, 徐梦, 李永勇*, 王培军*   

  1. 同济大学先进材料与纳米生物医学研究院 上海 200092; 同济大学附属同济医院医学影像科 上海 200065
  • 收稿日期:2010-07-01 修回日期:2010-10-01 出版日期:2011-04-24 发布日期:2011-02-25
  • 通讯作者: e-mail:yongyong_li@tongji.edu.cn; tongjipjwang@vip.sina.com E-mail:yongyong_li@tongji.edu.cn; tongjipjwang@vip.sina.com
  • 基金资助:

    上海市科委项目(SKW0403)、同济大学青年优秀人才培养行动计划、上海市自然科学基金项目(No.10ZR1432100)和上海市博士后基金项目(No.10R21415700)资助

下载PDF ( 2419 ) 引用
导出 被引次数 ( 14 | 1 )

Gadolinium-Based Contrast Agents for Tumor Targeting Imaging

Shen Aijun, Dong Haiqing, Wen Huiyun, Xu Meng, Li Yongyong*, Wang Peijun*   

  1. Institute for Advanced Materials & Nano Biomedicine, Tongji University, Shanghai 200092, China; Department of Medical Imaging, Tongji Hospital, Tongji University, Shanghai 200065, China
  • Received:2010-07-01 Revised:2010-10-01 Online:2011-04-24 Published:2011-02-25

核磁共振成像(MRI)是肿瘤诊断的重要手段,特别是各种造影剂的使用加速了临床应用范围。目前临床MRI检查所用各类造影剂如Gd-DTPA-BMA、Gd-DOTA等均为小分子造影剂,存在组织特异性低、体内停留时间短等缺点。构建具有组织特异性的新一代高效、低毒MRI造影剂成为材料界、医学界的研究热点之一。本文在综合最新文献的研究基础之上,重点关注含钆类造影剂在肿瘤靶向成像中的应用及发展。

关键词： 核磁共振成像, 造影剂, 钆, 肿瘤, 靶向成像

Magnetic resonance imaging (MRI) is an important technique of medical imaging for the tumor diagnosis, due to its high spatial and temporal resolutions and excellent soft tissue contrast, especially after the usage of various contrast agents.However,the currently contrast agents for MRI,such as Gd-DTPA-BMA,Gd-DOTA etc.,are all small molecules,which are associated with the intrinsic drawbacks such as nonspecificity for the interesting tissue,rapid excretion in vivo.To address the above questions,the novel specific MRI contrast agents with high efficiency and low toxicity,are thus becoming the hotspot research in both material and medical fields.In this review,particular attention is paid on the recent progress of gadolinium-based MRI contrast agents for tumor targeting imaging by summarizing the relevant research papers.Both passive and the active approach for tumor targeting imaging are involved in this review.The synthesis,principle and the determined factors of MRI contrast agents for tumor targeting imaging and their in vitro or in vivo effect on the interesting tissue are discussed.

Key words: magnetic resonance imaging (MRI), contrast agents, gadolinium, tumor, targeting imaging

中图分类号: 

()

[1] 陈星荣(Chen X R), 沈天真(Shen T Z), 段承祥(Duan C X)等. 全身CT和MRI(Whole Body CT and MRI). 上海: 上海医科大学出版社(Shanghai: Shanghai Medical University Press), 1994. 18
[2] 谢敬霞(Xie J X).核磁共振新技术研究与临床应用(NMR study and clinical application of new technologies) .北京:北京医科大学出版社(Beijing: Beijing Medical University Press), 2001. 1
[3] 罗毅(Luo Y), 卓仁禧(Zhuo R X), 史玉亭(Shi Y T). 国外医药(Foreign Medicine), 1995, 16: 200-208
[4] Mikawa M, Kato H, Okumura M, Narazaki M, Kanazawa Y, Miwa N, Shinohara H. Bioconjug. Chem., 2001, 12: 510-514
[5] 卢兴(Lu X), 徐建勋(Xu J X), 施祖进(Shi Z J), 孙宝云(Sun B Y), 顾镇南(Gu Z N), 刘洪东(Liu H D), 韩鸿宾(Han H B). 高等学校化学学报(Chemical Journal of Chinese Universities), 2004, 25: 697-700
[6] Zhang Z D, Nair S A, McMurry T J. Curr. Med. Chem., 2005, 12: 751-778
[7] Ehrlich P. The Collected Papers of Paul Ehrlich [M]. Oxford : Pergamon Press, 1960. 3: 510
[8] Li S D, Huang L. Mol. Pharm., 2008, 5: 496-504
[9] Mulder W J M, Strijkers G J, van Tilborg G A F, Griffioen A W, Nicolay K. NMR Biomed., 2006, 19: 142-164
[10] Kostarelos K, Emfietzoglon D. J. Liposome Res., 1999, 9: 429-460
[11] Kabalka G, Buonocore E, Hubner K, Moss T, Norley N, Huang L. Radiology, 1987, 163: 255-258
[12] Suzana T, Maria I M, Lothar H, et al. NMR Biomed., 2008, 21: 322-336
[13] 陈智金(Chen Z J), 张娜(Zhang N).中国新药杂志(Chinese Journal of New Drugs), 2009, 18: 1443-1447
[14] Schuhmann-Giamperi G, Schmitt-Willich H, Press W R, Negishi C, Wenimann H J, Speck U. Radiology, 1992, 183: 59-64
[15] Vittadini G, Felder E, Tirone P, Lorusso V. Invest. Radiol., 1988, 23: S246-S248
[16] Simon G H, Fu Y J, Berejnoi K, Fournier L S, LucidiV, Yeh B, Shames D M, Brasch R C. Invest. Radiol., 2005, 40: 614-620
[17] Bjornaes I, Rofstad E K. Magn. Reson. Imaging, 2001, 19: 723-730
[18] Axel G, Yoshitaka O, David M S, Thomas H H, Timothy P L ,Michael F W, Sabine H, Robert C B. Radiology, 1999, 213: 265-272
[19] Preda A, van Vliet M, Krestin G P, Brasch R C, Van Dijke C F. Invest. Radiol., 2006, 41: 325-331
[20] Davis I D, Desai J. Curr. Cancer Drug Targets, 2008, 8: 498-508
[21] Raatschen H J, Fu Y J, Shames D M, Wendland M F, Brasch R C. Invest. Radiol., 2006, 41: 860-867
[22] Cyran C C, Fu Y J, Raatschen H J, Rogut V, Chaopathomkul B, Shames D M, Wendland M F, Yeh B M, Brasch R C. J. Magn. Reson. Imaging, 2008, 27: 581-589
[23] Tannock I F, Rotin D. Cancer Res., 1989, 49: 4373-4384
[24] Vaupel P, Kallinowski F, Okunieff P, et al. Cancer Res., 1989, 49: 6449-6465
[25] Khramtsov V V. Curr. Org. Chem., 2005, 9: 909-923
[26] Lowe M P, Parker D, Reany O, Aime S, Botta M, Castellano G, Gianolio E, Pagliarin R. J. Am. Chem. Soc., 2001, 123: 7601-7609
[27] Aime S, Botta M, Crich S G, Giovenzana G, Palmisano G, Sisti M. Chem. Commun., 1999, 1577-1578
[28] Zhang S R, Wu K C, Sherry A D. Angew. Chem., 1999, 111: 3382-3384
[29] Ali M M, Woods M, Caravan P, Opnia A C L, Spiller M, Fettinger J C, Sherry A D. Chem. Eur. J., 2008, 14: 7250-7258
[30] Moghimi S M, Hunter A C, Murray J C. Pharmacol. Rev., 2001, 53: 283-318
[31] Jain R K. Cancer Metast. Rev., 1990, 9: 253-266
[32] Hanahan D, Weinberg R A. Cell, 2000, 100: 57-70
[33] Tannock I F, Lee C M, Tunggal J K, Cowan D S, Egorin M. J. Clin. Cancer Res., 2002, 8: 878-884
[34] 张莉(Zhang L), 潘 俊(Pan J), 陆伟跃(Lu W Y). 国外医药(Foreign Medicine), 2002, 23: 359-362
[35] Wang S C, Zhang L, Hortobagyi G N, Hung M C. Semin. Oncol., 2001, 28: 21-29
[36] Hortobagyi G N. Semin. Oncol., 2001, 28: 43-47
[37] Artemov D, Mori N, Ravi R, Bhujwalla Z M. Cancer Res., 2003, 63: 2723-2727
[38] Sabharanjak S, Mayor S. Adv. Drug Deliver. Rev., 2004, 56: 1099-1109
[39] Ross J F, Chaudhuri P K, Ratnam M. Cancer, 1994, 73:2432-2443
[40] Sega E I, Low P S. Cancer Metast. Rev., 2008, 27: 655-664
[41] Corot C, Robert P, Lancelot E, Prigent P, Ballet S, Guilbert I, Raynaud J S, Raynal I, Port M. Magn. Reson. Med., 2008, 60: 1337-1346
[42] Swanson S D, Kukowska-Latallo J F, Patri A K, Chen C Y, Ge S, Cao Z Y, Kotlyar A, East A T, Baker J R. Int. J. Nanomed., 2008, 3: 201-210
[43] Wiener E C, Konda S D, Wang S, Brechbiel M. Acad. Radiol., 2002, 9: S316-S319
[44] Corbin I R, Li H, Chen J, Lund-Katz S, Zhou R, Glickson J D, Zheng G. Neoplasia, 2006, 8: 488-498
[45] Li H, Gray B D, Corbin L, Lebherz C, Choi H, Lund-Katz S, Wilson J M, Glickson J D, Zhou R. Acad. Radiol., 2004, 11: 1251-1259
[46] Pirollo K F, Dagata J, Wang P, Freedman M, Vladar A, Fricke S, Ileva L, Zhou Q, Chang E H. Mol. Imaging, 2006, 5: 41-52
[47] Freedman M, Chang E H, Zhou Q, Pirollo K F. Acad. Radiol., 2009, 16: 627-637
[48] 王秩秋(Wang Z Q), 单良(Shan L), 王颂平(Wang S P),Korotcov A, 梁兴杰(Liang X J).生物物理学报(Acta Biophysica Sinica), 2008, 24: 315-320
[49] White M K, Mccubrey J A. Int. J. Oncol., 1995, 7: 701-712
[50] Luciani A, Olivier J C, Clement O, Siauve N, Brillet P Y, Bessoud B, Gazeau F, Uchegbu L F, Kahn E, Frijia G, Cuenod C A. Radiology, 2004, 231: 135-142
[51] 姜树红(Jiang S H), 戈延茹(Ge Y R), 单秀红(Shan X H),莫传杰(Mo C J), 陈智贤(Chen Z X). 中国医院药学杂志(Chinese Journal of Hospital Pharmacy), 2008, 28: 1916-1918
[52] Medina M A, Sánchez-Jiménez F, Márquez J, Quesada A R. Mol. Cell. Biochem., 1992, 113: 1-15
[53] Souba W W. Ann. Surg., 1993, 218: 715-728
[54] Lattuada L, Demattio S, Vincenzi V, Cabella C, Visigalli M, Aime S, Crich S G, Gianolio E. Bioorg. Med. Chem. Lett., 2006, 16: 4111-4114
[55] Park J H, Lee S, Kim J H, Park K, Kim K, Kwon I C. Prog. Polym. Sci., 2008, 33: 113-137
[56] Park J A, Lee J J, Jung J C, Yu D Y, Oh C, Ha S, Kim T J, Chang Y M. Chem. Bio. Chem., 2008, 9: 2811-2813
[57] Zarabi B, Borgman M P, Zhuo J C, Gullapalli R, Ghandehari H. Pharm. Res., 2009, 26: 1121-1129
[58] Mulder W J M, Strijkers G J, Griffioen A W, Bloois L, Molema G, Storm G, Koning G A, Nicolay K. Bioconjug. Chem., 2004, 15: 799-806
[1] 顾顺心, 姜琴, 施鹏飞. 发光铱(Ⅲ)配合物抗肿瘤活性研究及应用[J]. 化学进展, 2022, 34(9): 1957-1971.
[2] 冯海弟, 赵璐, 白云峰, 冯锋. 纳米金属有机框架在肿瘤靶向治疗中的应用[J]. 化学进展, 2022, 34(8): 1863-1878.
[3] 陈晓峰, 王开元, 梁芳铭, 姜睿祺, 孙进. 外泌体递药系统及其在肿瘤治疗中的应用[J]. 化学进展, 2022, 34(4): 773-786.
[4] 王嘉莉, 朱凌, 王琛, 雷圣宾, 杨延莲. 循环肿瘤细胞及细胞外囊泡的纳米检测技术[J]. 化学进展, 2022, 34(1): 178-197.
[5] 荆晓东, 孙莹, 于冰, 申有青, 胡浩, 丛海林. 肿瘤微环境响应药物递送系统的设计[J]. 化学进展, 2021, 33(6): 926-941.
[6] 许惠凤, 董永强, 朱希, 余丽双. 新型二维材料MXene在生物医学的应用[J]. 化学进展, 2021, 33(5): 752-766.
[7] 赵平平, 杨军星, 施健辉, 朱静怡. 基于树状大分子的SPECT成像造影剂的构建及其应用[J]. 化学进展, 2021, 33(3): 394-405.
[8] 刘加伟, 王婧, 王其, 范曲立, 黄维. 激活型有机光声造影剂的应用[J]. 化学进展, 2021, 33(2): 216-231.
[9] 王欣瑜, 赵富平, 张儒, 孙子茹, 刘胜男, 高清志. 抗肿瘤缺氧诱导因子-1的小分子抑制剂[J]. 化学进展, 2021, 33(12): 2259-2269.
[10] 官启潇, 郭和泽, 窦红静. 细胞膜修饰的纳米载体与肿瘤免疫治疗[J]. 化学进展, 2021, 33(10): 1823-1840.
[11] 郭珊, 周翔. 循环肿瘤细胞体内检测技术及其应用研究[J]. 化学进展, 2021, 33(1): 1-12.
[12] 吴晴, 唐一源, 余淼, 张悦莹, 李杏梅. 基于肿瘤微环境响应的DNA纳米结构递药系统[J]. 化学进展, 2020, 32(7): 927-934.
[13] 孙子茹, 刘胜男, 高清志. 靶向葡萄糖转运蛋白(GLUTs)抗癌药物的开发[J]. 化学进展, 2020, 32(12): 1869-1878.
[14] 宫苗, 王晓英, 王晓宁. 血液肿瘤相关生物标志物的电化学传感检测[J]. 化学进展, 2019, 31(6): 894-905.
[15] 徐子悦, 张运昌, 林佳乐, 王辉, 张丹维, 黎占亭. 药物输送体系构筑中的超分子组装策略[J]. 化学进展, 2019, 31(11): 1540-1549.
阅读次数
全文


摘要

钆类造影剂用于肿瘤靶向性成像